Tower Research Capital LLC (Trc) Monopar Therapeutics Transaction History
Tower Research Capital LLC (Trc)
- $5.8 Billion
- Q2 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Monopar Therapeutics stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 7,922 shares of MNPR stock, worth $122,236. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,922
Previous 7,856
0.84%
Holding current value
$122,236
Previous $5,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding MNPR
# of Institutions
10Shares Held
379KCall Options Held
0Put Options Held
0-
Israel Englander Millennium Management LLC | New York, Ny194KShares$3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA60KShares$926,3550.0% of portfolio
-
Two Sigma Securities, LLC New York, NY47.1KShares$726,1040.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA45.2KShares$696,9260.0% of portfolio
-
Virtu Financial LLC New York, NY18.8KShares$290,7010.0% of portfolio
About Monopar Therapeutics
- Ticker MNPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,725,800
- Market Cap $196M
- Description
- Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...